Clinical Trial Update: Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating evobrutinib in relapsing-remitting multiple sclerosis was terminated, with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Evobrutinib (evobrutinib)

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Relapsing-remitting Multiple Sclerosis | Phase 3 | Status: TERMINATED | Results posted: 2021-08-05